WO2018149929A1 - Dosages de gènes rapporteurs et analyse transcriptionnelle combinés - Google Patents

Dosages de gènes rapporteurs et analyse transcriptionnelle combinés Download PDF

Info

Publication number
WO2018149929A1
WO2018149929A1 PCT/EP2018/053810 EP2018053810W WO2018149929A1 WO 2018149929 A1 WO2018149929 A1 WO 2018149929A1 EP 2018053810 W EP2018053810 W EP 2018053810W WO 2018149929 A1 WO2018149929 A1 WO 2018149929A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cell
based assay
qpcr
probe
Prior art date
Application number
PCT/EP2018/053810
Other languages
English (en)
Inventor
Stefan Golz
Svenja KLEIMANN
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of WO2018149929A1 publication Critical patent/WO2018149929A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A61K49/0047—Green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the present invention relates to the field of molecular and cell biology, more particularly, the present invention relates to a method which combines two or more techniques to analyse the effects of compounds on cells or tissues.
  • the invention also relates to a method which combines methods for the analysis or quantification of RNA with methods to measure second messenger signaling or promotor activity.
  • HTS is performed, for example, in 1536-well plates with assay volumes between 5-10 ⁇ . This set up, together with fully-automated robotic systems allows for testing in excess of 200,000 compounds per day. Comprehensive substance collections together with sophisticated screening technologies have resulted in a clear advantage in lead discovery especially for poorly draggable targets. The productivity of HTS has recently been questioned, because often no modulators could be found for a given target, and the poor drugability of many molecular targets pursued in research programs, together with a poor quality of compounds in screening libraries, have been identified as major drawbacks responsible for low success. Improvements in the design of library screening methods aim at the identification of compounds with more "drug-like" physico-chemical properties, like oral availability. Summary of the invention
  • embodiments disclosed herein are not meant to be understood as individual embodiments which would not relate to one another.
  • Features discussed with one embodiment are meant to be disclosed also in connection with other embodiments shown herein. If, in one case, a specific feature is not disclosed with one embodiment, but with another, the skilled person would understand that does not necessarily mean that said feature is not meant to be disclosed with said other embodiment. The skilled person would understand that it is the gist of this application to disclose said feature also for the other embodiment, but that just for purposes of clarity and to keep the specification in a manageable volume this has not been done.
  • the content of the prior art documents referred to herein is incorporated by reference. This refers, particularly, to prior art documents that disclose standard or routine methods. In that case, the incorporation by reference has mainly the purpose to provide sufficient enabling disclosure, and avoid lengthy repetitions.
  • a method for analysing the effects of one or more test compounds on cells or tissues comprising at least
  • ( ⁇ ) a step comprising an expression analysis related to said cells or tissues.
  • the combination of a cell-based assay and an expression analysis readout has a number of unexpected advantages, namely, saving of time, saving of resources, enhanced assay accuracy, and combination of data from different pathway levels.
  • cell-based assay relates to methods using defined cells, which are then exposed the test compounds.
  • Biochemical assays are target-based in vitro assays which historically have been the mainstay of high throughput screening (HTS) in the pharmaceutical industry. Such assays include assessment of enzymatic activity (e.g. for kinases, proteases, or transferases), receptor-ligand binding (e.g., for G-protein coupled receptors (GPCRs), ion channels , or nuclear receptors), or protein-protein interactions. Biochemical assays are often direct and specific to the target of interest and can be miniaturized readily. However, not all targets can be purified or prepared in a manner suitable for biochemical measurement. Additionally, a certain activity of a small molecule observed in an in vitro assay does not always translate into the same activity in a cellular context, because of issues including membrane permeability, off-target effects, and cytotoxicity [Tolliday, 2009].
  • cell-based assays do not require an a priori knowledge of the target that might be affected by the test compounds. Further, in contrast to biochemical assays, the likelihood that a extrapolation from assay results into a living system can be done is much higher. In most cell based assays, entire pathways of interest can be interrogated, providing the opportunity for multiple potential intervention points, as opposed to a single predefined step with the biochemical approach. Examples for cell based assays formats are (but not limited to) proliferation assays, reporter gene assays, second messenger assays and high content screening assays. In such way, parameters such as potential drug cytotoxicity, mechanism of action, and biological activity can be determined.
  • expression analysis relates to a method involving the qualitative or quantitative determination of the expression of one gene, or a set of gene, either measured on the protein level or on the mRNA level.
  • the cell-based assay format is based on measuring second messenger signaling or promotor activity [Roda, 2010].
  • said cell- based assay format is a reporter gene based assay format.
  • cells can be engineered to express specific gene products in response to a given stimulus.
  • the gene product itself may possess an inherent property that enables it to be measured directly, e.g., green fluorescent protein (GFP), or it may display enzymatic activity that can be monitored, e.g., luciferase.
  • the gene product may respond to changes in the levels of a signaling molecule, e.g., the Ca 2+ ion-mediated activation of aequorin luminescence.
  • GFP green fluorescent protein
  • the gene product may respond to changes in the levels of a signaling molecule, e.g., the Ca 2+ ion-mediated activation of aequorin luminescence.
  • the choice of a particular promoter, the number of promoter copies per reporter gene unit, and the nature of the reporter gene allow to control the basal level of reporter gene activityand control of the degree of stimulation measured.
  • Endogenous promoters such as c-fos, the cAMP response element (CRE), or the estrogen response element are commonly used.
  • CRE cAMP response element
  • the accuracy of assays employing these promoters istheir activation through endogenous intracellular signaling events.
  • the reporter gene itself should ultimately generate a signal that can be clearly identified.
  • the reporter gene products can be either intracellular or extracellular in nature. Intracellular products are retained in the cell for quantification in situ or following cell lysis.
  • Extracellular products are secreted into the extracellular medium for assay, allowing repeated experimentation and sampling without disrupting the cells.
  • Commonly used intracellular reporter genes are chloramphenicol acetyltransferase (CAT), ⁇ -galactosidase, luciferase, aequorin, and GFP.
  • Extracellular reporter genes are usually secreted placental alkaline phosphatase (SPAP) or ⁇ - lactamase [Tolliday, 2009].
  • a reporter gene is chosen the gene product of which can easily be detected with standard biochemical or histochemical methods.
  • Two commonly used types of reporter genes are resistence genes and reporter genes.
  • Resistance genes are genes, the expression of which confers on a cell the resistance to antibiotics or other substances which would, in the absence of the resistence gene, cause the death of the cell.
  • reporter genes or proteins can be fused to a target genes to detect expression thereof by luminescent or fluorescent readouts (e.g. GFP, luciferase), namely because the reporter gene is coexpressed with the target gene.
  • luminescent or fluorescent readouts e.g. GFP, luciferase
  • said cell- based assay format is at least one selected from the group consisting of:
  • Luminescence is the term given to the emission of photons in the visible spectral range, with this emission being brought about by excitated emitter molecules. In contrast to fluorescence, the energy for this is not supplied externally in the form of radiation of shorter wavelength.
  • chemiluminescence is the term given to a chemical reaction which leads to an excited molecule which itself emits light when the excited electrons return to the normal energy level.
  • Bioluminescence is the term used when this reaction is catalyzed by an enzyme.
  • the enzymes which participate in the reaction are generally termed luciferases. Luciferases are peroxidases or monooxygenases and dioxygenases.
  • the enzyme substrates, which form the starting substances for the light- emitting products, are termed luciferins. They differ from species to species.
  • the quantum yield of the systems lies between 0.1 and 0.9 photons per transformed substrate molecule.
  • Luciferases can be classified on the basis of their origin or their enzymic properties. Luciferases can also be distinguished from each other on the basis of their substrate specificity. The most important substrates include coelenterazine and luciferin, and also derivatives of the two substances. An overview, but not limited to, of some luciferases:
  • Renilla Luciferase (Renilla reniformis) - substrate Coelenterazine
  • Watasemia Luciferase (Watasenia scintillans) - substrate Watasemia Luciferin
  • Olophorus Luciferase (Olophorus gracilirostris) - substrate Coelenterazine
  • Firefly Luciferase (Photinus pyralis) - substrate: Firefly Luciferin
  • Hydozoa (aequoria, halistaura obelia) and anthropods (acanthotilum, sea cactus, cavernularia, renila, ptilosarcus, stylatula).
  • ⁇ Green fluorescent protein (Aequorea macrodactyla, Gene ID: AF435433)
  • Green fluorescent protein Heteractis crispa, Gene ID: AF420592
  • Green fluorescent protein-like protein (Montastraea annularis, Gene ID: AY037766)
  • Green fluorescent protein-like protein (Montastraea cavernosa, Gene ID: AY037768)
  • Cyan fluorescent protein (Montastraea cavernosa, Gene ID: AY056460)
  • Green fluorescent protein (Renilla muelleri, Gene ID: AY015996)
  • Green fluorescent protein (Renilla renoformis, Gene ID: AF372525)
  • Green fluorescent protein- like protein (Ricordea florida, Gene ID: AY037774)
  • the fluorescent proteins differ from one another not only due to their nucleotide and amino acid sequences but also due to their biochemical and physical properties.
  • the spectral characteristics of the fluorescent proteins may differ both on the side of excitation and on the side of emission.
  • Fluorescence-based assays can be generally divided into two classes.
  • the first class encompasses techniques that macroscopically detect the total fluorescence intensity, fluorescence polarization, fluorescence resonance energy transfer (FRET), fluorescence lifetime, time-resolved fluorescence, and combinations of these techniques, such as time-resolved fluorescence polarization.
  • the second class of fluorescence-based assays detects fluorescence from single fluorescent molecules, such as fluorescence correlation spectroscopy and fluorescence intensity distribution analysis. These fluorescence techniques have been used to monitor an enormous collection of biological processes, such as macromolecule-macromolecule interactions, macromolecule-small molecule interactions, enzymatic activities, signal transduction, cell health, and states and locations of molecules, organelles, or cells [Tolliday, 2009] .
  • Fluorescence resonance energy transfer utilises non-radiative energy transfer from a donor fluorophore to an acceptor fluorophore resulting in fluorescence emission from the acceptor.
  • FRET can occur where there is sufficient overlap of the donor emission spectrum with the acceptor excitation spectrum, close proximity ( ⁇ 100 A) and correct donor-acceptor orientation of dipole moments. These parameters are readily adaptable to ligand binding assays, where binding of a fluorescent ligand with suitable spectral properties to a fluorophore-tagged protein provides the close proximity required for FRET.
  • FRET assays require the target protein to be tagged with a donor or acceptor fluorophore, this can be achieved by fusing the N-terminus of the protein with a fluorescent protein (such as EGFP) [Pfleger, 2015] .
  • a fluorescent protein such as EGFP
  • FA fluorescence anisotropy
  • the transcriptome is defined as the full complement of RNA transcripts of the genes of a cell or organism.
  • the types and relative abundance of different transcripts i.e. the messenger RNAs (mRNAs)
  • mRNAs messenger RNAs
  • This analysis is defined as transcriptomics.
  • Used methods for transcriptome analysis are, but not limited to, sequencing, microarrays and PCR-based methods (e.g. QPCR).
  • the expression analysis of said cells or tissues comprises an RNA quantification.
  • the expression analysis of said cells or tissues comprises a QPCR or RT-PCR.
  • RT-PCR means "real-time polymerase chain reaction” while the term QPCR means "quantitative polymerase chain reaction”
  • RT-PCR is a laboratory technique of molecular biology based on the polymerase chain reaction (PCR). It monitors the amplification of a targeted DNA molecule during the PCR, i.e. in real-time, and not at its end, as in conventional PCR.
  • Real-time PCR can be used quantitatively (Quantitative real-time PCR), semi-quantitatively (Semi quantitative real-time PCR) or qualitatively (Qualitative real-time PCR).
  • Two common methods for the detection of PCR products in real-time PCR are: (1) non-specific fluorescent dyes that intercalate with any double-stranded DNA, and (2) sequence-specific DNA probes consisting of oligonucleotides that are labelled with a fluorescent reporter which permits detection only after hybridization of the probe with its complementary sequence.
  • Real-time PCR is carried out in a thermal cycler with the capacity to illuminate each sample with a beam of light of at least one specified wavelength and detect the fluorescence emitted by the excited fluorophore.
  • the thermal cycler is also able to rapidly heat and chill samples, thereby taking advantage of the physicochemical properties of the nucleic acids and DNA polymerase.
  • the PCR process generally consists of a series of temperature changes that are repeated 25 - 50 times. These cycles normally consist of three stages: the first, at around 95 °C, allows the separation of the nucleic acid's double chain; the second, at a temperature of around 50-60 °C, allows the binding of the primers with the DNA template; [Rhoads, 1990] the third, at between 68 - 72 °C, facilitates the polymerization carried out by the DNA polymerase. Due to the small size of the fragments the last step is usually omitted in this type of PCR as the enzyme is able to increase their number during the change between the alignment stage and the denaturing stage.
  • the fluorescence is measured during short temperature phase lasting only a few seconds in each cycle, with a temperature of, for example, 80 °C, in order to reduce the signal caused by the presence of primer dimers when a non-specific dye is used.
  • the temperatures and the timings used for each cycle depend on a wide variety of parameters, such as: the enzyme used to synthesize the DNA, the concentration of divalent ions and deoxyribonucleotides (dNTPs) in the reaction and the bonding temperature of the primers.
  • Probes used in multiplex assays are conjugated with fluorescent reporter dyes, which vary in their absorption and emission spectra.
  • the number of genes that can be analyzed in the same tube is limited by spectral properties of the available fluorophores, which should have nonoverlapping emission spectra for separate detection.
  • the majority of modern spectrofluorometric thermal cyclers allow the measurement of fluorescence in four different wavelength channels (although six- channel machines do exist), thereby enabling the concurrent detection of up to four different DNA targets.
  • a choice of dyes optimized for detection in each channel is available for distinctive labelling of specific probes.
  • TaqMan is a technique in which the release of a fluorescent reporter dye from a hybridisation probe in real-time during a polymerase chain reaction (PCR) is proportional to the accumulation of the PCR product. Quantification is based on the early, linear part of the reaction, and by determining the threshold cycle (CT), at which fluorescence above background is first detected.
  • CT threshold cycle
  • the most widely used probes to monitor DNA amplification in real-time PCR in clinical settings are TaqMan or hydrolysis probes [Williams, 1996]. These probes are labeled at one end with a reporter fluorescent dye and on the other with a fluorescence quencher, which must exhibit spectral overlap with the fluorophore.
  • Quencher absorbs energy emitted by the flourophore through fluorescent resonance energy transfer (FRET); the quenchers, currently used in multiplex PCR, reemit energy as heat (dark quencher).
  • FRET fluorescent resonance energy transfer
  • the quenchers currently used in multiplex PCR, reemit energy as heat (dark quencher).
  • the Tm of the probe is usually 8-10°C higher than that of the primers, which allows the probe to anneal prior to extension.
  • the 5 -exonuclease activity of the Taq polymerase hydrolyses the bound probe and releases the dye from the quencher, relieving quenching effect. The level of detected fluorescence is therefore proportional to the amounts of newly synthesized DNA.
  • Hybridization probes consist of two single-dye labeled oligonucleotides which bind to adjacent targets in the amplified region, thereby bringing the two dyes in close proximity and inducing FRET.
  • Molecular beacon probes are designed as hairpins, with target sequence located in the loop and fluorescent dye and the quencher conjugated to the 5'-end and 3'-end of the oligonucleotide. In the intact, hairpin state, fluorescence is quenched; binding of the probe to the amplified sequence forces fluorophore and quencher apart, and releases fluorescent signal.
  • Scorpion primers Another widely used probes are Scorpion primers, which combine PCR primer and specific probe in one sequence [Little, 1999].
  • the structure of Scorpion primers promotes unimolecular probing mechanism; consequently, they can perform better than TaqMan probes or molecular beacons particularly under fast cycling conditions [Brown, 2000].
  • Described probes can be used not only to quantify levels of DNA, but to discriminate between alleles and detect mutations as well [Skoblov, 2011].
  • the cell-based assay format is a luciferase based assay format, and wherein said expression analysis of said cells or tissues is a QPCR or RT-PCR.
  • said cells are prokaryotic or eukaryotic cells.
  • said cells are selected from the group comprising human cells, animal cells, plant cells, microbial cells, and bacterial cells.
  • at least one of the steps is performed in at least one microtiter plate having a number of sample wells selected from the group consisting of 6, 24, 96, 384, 1536, 3072, 3456, 6144 and 9600 wells.
  • a microtiter plate or microplate or microwell plate or multiwell is a flat plate with multiple "wells" used as small test tubes.
  • the microplate has become a standard tool in analytical research and clinical diagnostic testing laboratories.
  • a microplate typically has, but not limited to, 6, 24, 96, 384, 1536, 3072, 6144 sample wells or even more arranged in a 2:3 rectangular matrix.
  • Some microplates have even been manufactured with 3456 or even 9600 wells, and an "array tape" product has been developed that provides a continuous strip of microplates embossed on a flexible plastic tape.
  • Each well of a microplate typically holds somewhere between tens of nanolitres to several millilitres of liquid. Wells can be either circular or square.
  • robots to specifically handle microplates. These robots may be liquid handlers which aspirate or dispense liquid samples from and to these plates, or "plate movers" which transport them between instruments, plate stackers which store microplates during these processes, plate hotels for longer term storage, plate washers for processing plates, plate thermal sealers for applying heat seals, de-sealers for removing heat seals, or microplate incubators to ensure constant temperature during testing. Instrument companies have designed plate readers which can detect specific biological, chemical or physical events in samples stored in these plates. Microtiter plates could be used for different cell-based assays formats, as well as expression analysis (e.g. QPCR).
  • QPCR expression analysis
  • microtiter plates allows the screening of libraries and or the integration into High Throughput Screening (HTS) enivironments, as discussed elsewhere herein.
  • HTS High Throughput Screening
  • a cell lysate or cell culture supernatant derived from the cell based assay step is subjected to the expression analysis step.
  • a method of screening a library of test compounds is provided, which method encompasses a method according to the above description.
  • library relates to a plurality of compounds of similar kind, e.g., a library of antibodies, a library of small molecules, or a library of aptamers. These libraries can have a size of anything between 5 to 10 15 individual compounds.
  • kits of parts comprising reagents suitable for performing the method according to the above description.
  • the use of such kit of parts is provided for identifying a particular gene or gene product to be a potential target for the action of potentially therapeutic agents.
  • the use of such kit of parts is provided for screening one or more test compounds which are potentially therapeutic agents, or a library thereof, for the development of a pharmaceutical drug.
  • the potentially therapeutic agents are preferably (i) biologies or (ii) small molecules.
  • biological refers to (i) protein-based moelcules, (ii) nucleic-acid an based molecules or (iii) cells or cell comprising entities, all of which have a physiological effect, preferably a therapeutic effect.
  • Molecules encompassed by that term are vaccines, cytokines, hormones, coagulation factors, antibodies and antibody-derived molecules, antibody mimetics, aptamers, RNA molecules and the like, and blood products and the like.
  • Cells or cell comprising entities encompassed by that term are stem cells and T cells, including transgenic or chimerized variants thereof, and cellular blood products and the like.
  • small molecule refers to a non-peptidic, non-oligomeric organic compound either synthesized in the laboratory or found in nature.
  • Small molecules can refer to compounds that are "natural product- like", however, the term “small molecule” is not limited to "natural product-like” compounds. Rather, a small molecule is typically characterized in that it contains several carbon-carbon bonds, and has a molecular weight of less than 2500, although this characterization is not intended to be limiting for the purposes of the present invention.
  • oligonucleotide as used herein is a stretch of nucleotide residues which has a sufficient number of bases to be used as an oligomer, amplimer or probe in a polymerase chain reaction (PCR). Oligonucleotides can be prepared from genomic or cDNA sequence and are used to amplify, reveal, or confirm the presence of a similar DNA or RNA in a particular cell or tissue. Oligonucleotides or oligomers comprise portions of a DNA sequence having at least about 10 nucleotides and as many as about 35 nucleotides, preferably about 25 nucleotides. "Probes" as used herein refers to nucleic acid probes.
  • nucleic acid probes may be used in southern, northern, PCR based methods, hybridisation based methods or in situ hybridizations to determine whether DNA or RNA encoding a certain protein is present in a cell type, tissue, organ or fluid.
  • Cells as used herein encompass prokaryotic and/or eukaryotic cells of a defined cell line, primary cells (a cell or cell line taken directly from a living organism, which is not immortalized), cells isolated from defined tissues or cell within a tissue from different species.
  • Primary cells a cell or cell line taken directly from a living organism, which is not immortalized
  • cells isolated from defined tissues or cell within a tissue from different species are examples of prokaryotic cells of a defined cell line, primary cells (a cell or cell line taken directly from a living organism, which is not immortalized), cells isolated from defined tissues or cell within a tissue from different species.
  • Primary cells a cell or cell line taken directly from a living organism, which is not immortalized
  • Prokaryotes refers to bacteria and archaea.
  • the labeled probe is selected so that its sequence is substantially complementary to a segment of the test locus or a reference locus. As indicated above, the nucleic acid site to which the probe binds should be located between the primer binding sites for the upstream and downstream amplification primers.
  • the primers used in the amplification are selected so as to be capable of hybridizing to sequences at flanking regions of the locus being amplified.
  • the primers are chosen to have at least substantial complementarity with the different strands of the nucleic acid being amplified.
  • the primers are selected in such that they flank the probe, i.e. are located upstream and downstream of the probe.
  • the primer must have sufficient length so that it is capable of priming the synthesis of extension products in the presence of an agent for polymerization.
  • the length and composition of the primer depends on many parameters, including, for example, the temperature at which the annealing reaction is conducted, proximity of the probe binding site to that of the primer, relative concentrations of the primer and probe and the particular nucleic acid composition of the probe.
  • the primer includes 15-30 nucleotides.
  • the length of the primer may be more or less depending on the complexity of the primer binding site and the factors listed above.
  • the labels used for labeling the probes or primers of the current invention and which can provide the signal corresponding to the quantity of amplification product can take a variety of forms.
  • a fluorescent signal is one signal which can be measured.
  • measurements may also be made, for example, by monitoring radioactivity, colorimetry, absorption, magnetic parameters, or enzymatic activity.
  • labels which can be employed include, but are not limited to, fluorophors, chromophores, radioactive isotopes, electron dense reagents, enzymes, and ligands having specific binding partners (e.g., biotin-avidin).
  • a number of labels useful for attachment to probes or primers are commercially available including fluorescein and various fluorescein derivatives such as, but not limited to FAM, HEX, TET and JOE; lucifer yellow, and coumarin derivatives.
  • Labels may be attached to the probe or primer using a variety of techniques and can be attached at the 5' end, and/or the 3' end and/or at an internal nucleotide.
  • the label can also be attached to spacer arms of various sizes which are attached to the probe or primer. These spacer arms are useful for obtaining a desired distance between multiple labels attached to the probe or primer.
  • a single label may be utilized; whereas, in other instances, such as with the 5' fluorogenic nuclease assays for example, two or more labels are attached to the probe.
  • the probe includes multiple labels, it is generally advisable to maintain spacing between the labels which is sufficient to permit separation of the labels during digestion of the probe through the 5'-3' nuclease activity of the nucleic acid polymerase.
  • fluorescent acceptor molecules like TAMRA
  • Quenchers are chemically related to fluorophores but instead of emitting absorbed fluorescence resonance energy as light they have the useful property of transforming the light energy to heat.
  • Heat dissipation of fluorescence energy means that replacing a fluorescent acceptor like TAMRA with a quencher such as Iowa Black TM FQ will result in an oligonucleotide construct that has no measurable fluorescence as long as the oligonucleotide tether remains intact.
  • Such constructs can greatly simplify many fluorescence assays since they do not have background fluorescence.
  • fluorophore - quencher dual - labeled probes have become a standard in kinetic (real-time) PCR. Quenchers absorb fluorophore emission energies over a wide range of wavelengths. This expanded dy namic range greatly adds to the utility of fluorescence quenchers, particularly in the case of multiplexing assays with different fluorophores [Integrated DNA Technologies, 2002].
  • Multiplexing is defined as the screening of multiple targets, the use of different reporter genes within the same experiment, or the combination of many signals into a single transmission circuit or channel [Miret et al., 2005]. Multiplexing allows for the parallel processing of multiple targets and promises to increase efficiencies, reduce costs, and improve the quality and content of screening data. In addition, it can also simplify the construction and execution of target selectivity panels.
  • the use of multiplexing in hit discovery has been previously reported for kinases, nuclear receptors, and GPCRs. Common strategies of cell-based multiplexing assay approaches are combinations of glow- and flash-light reporter genes or reporter genes with different substrate specificity.
  • Fluorogenic nuclease assays are a real time quantitation method that uses a probe to monitor formation of amplification product.
  • the basis for this method of monitoring the formation of amplification product is to measure continuously PCR product accumulation using a dual-labelled fluorogenic oligonucleotide probe, an approach frequently referred to in the literature simply as the "TaqMan method".
  • the probe used in such assays is typically a short (about 20-25 bases) oligonucleotide that is labeled with two different fluorescent dyes.
  • the 5' terminus of the probe is attached to a reporter dye and the 3' terminus is attached to a quenching dye, although the dyes could be attached at other locations on the probe as well.
  • the probe is designed to have at least substantial sequence complementarity with the probe binding site. Upstream and downstream PCR primers which bind to flanking regions of the locus are added to the reaction mixture. When the probe is intact, energy transfer between the two fluorophors occurs and the quencher quenches emission from the reporter.
  • the probe is cleaved by the 5' nuclease activity of a nucleic acid polymerase such as Taq polymerase, thereby releasing the reporter from the oligonucleotide- quencher and resulting in an increase of reporter emission intensity which can be measured by an appropriate detector.
  • Computer software is capable of recording the fluorescence intensity of reporter and quencher over the course of the amplification. The recorded values will then be used to calculate the increase in normalized reporter emission intensity on a continuous basis. The increase in emission intensity is plotted versus time, i.e., the number of amplification cycles, to produce a continuous measure of amplification.
  • the amplification plot is examined at a point during the log phase of product accumulation. This is accomplished by assigning a fluorescence threshold intensity above background and determining the point at which each amplification plot crosses the threshold (defined as the threshold cycle number or Ct or CP). Differences in threshold cycle number are used to quantify the relative amount of PCR target contained within each tube. Assuming that each reaction functions at 100% PCR efficiency, a difference of one Ct represents a two-fold difference in the amount of starting template. The fluorescence value can be used in conjunction with a standard curve to determine the amount of amplification product present.
  • These detection methods involve some alteration to the structure or conformation of a probe hybridized to the locus between the amplification primer pair.
  • the alteration is caused by the template-dependent extension catalyzed by a nucleic acid polymerase during the amplification process.
  • the alteration generates a detectable signal which is an indirect measure of the amount of amplification product formed.
  • some methods involve the degradation or digestion of the probe during the extension reaction. These methods are a consequence of the 5'-3' nuclease activity associated with some nucleic acid polymerases.
  • Polymerases having this activity cleave mononucleotides or small oligonucleotides from an oligonucleotide probe annealed to its complementary sequence located within the locus.
  • the 3' end of the upstream primer provides the initial binding site for the nucleic acid polymerase.
  • the nucleic acid polymerase displaces a portion of the 5' end of the probe and through its nuclease activity cleaves mononucleotides or oligonucleotides from the probe.
  • the upstream primer and the probe can be designed such that they anneal to the complementary strand in close proximity to one another. In fact, the 3' end of the upstream primer and the 5' end of the probe may abut one another. In this situation, extension of the upstream primer is not necessary in order for the nucleic acid polymerase to begin cleaving the probe.
  • nucleic acid polymerase In the case in which intervening nucleotides separate the upstream primer and the probe, extension of the primer is necessary before the nucleic acid polymerase encounters the 5' end of the probe. Once contact occurs and polymerization continues, the 5'-3' exonuclease activity of the nucleic acid polymerase begins cleaving mononucleotides or oligonucleotides from the 5' end of the probe. Digestion of the probe continues until the remaining portion of the probe dissociates from the complementary strand.
  • the two end sections can hybridize with each other to form a hairpin loop.
  • the reporter and quencher dye are in sufficiently close proximity that fluorescence from the reporter dye is effectively quenched by the quencher dye.
  • Hybridized probe in contrast, results in a linearized conformation in which the extent of quenching is decreased.
  • a variety of options are available for measuring the amplification products as they are formed.
  • One method utilizes labels, such as dyes, which only bind to double stranded DNA.
  • amplification product which is double stranded
  • dyes it is possible to distinguish between dye molecules free in solution and dye molecules bound to amplification product.
  • certain dyes fluoresce only when bound to amplification product. Examples of dyes which can be used in methods of this general type include, but are not limited to, Syber Green.TM. and Pico Green from Molecular Probes, Inc.
  • Molecule beacons enable dynamic, real - time detection of nucleic acid hybridization events both in vitro and in vivo.
  • One of the primary advantages of molecular beacons is that they can discriminate between targets that differ by as little as a single base pair change, making them ideal for investigating single nucleotide polymorphisms (SNPs).
  • Molecular beacons are designed so that probe sequence is sandwiched between complementary sequences that form the hairpin stem.
  • Molecular beacons must be designed so that the transition between two conformational states - the hairpin and the probe: target duplex is thermodynamically favorable. The temperature and the buffer used will influence probe specificity and must be carefully controlled.
  • the melting temperature of both the hairpin structure and the probe:target duplex shou Id be 7-10 oC higher than the temperature used for detection or for primer annealing.
  • a perfect match probe- target hybrid will be energetically more stable than the stem-loop structure whereas a mismatched probe target hybrid will be energetically less stable than the stem-loop structure.
  • This characteristic is the basis of the extraordinary specificity offered by molecular beacons. Specificity can also be relaxed by making the probe sequence in the loop and the probe - target hybrid more stable [Integrated DNA Technologies, 2002].
  • Scorpions probes consist of a primer covalent tly linked to a spacer region followed by a probe that contains a fluorophore and a quencher.
  • the probe contains a specific, complementary target sequence, a spacer region which forms a self - complementary stem, a fluorophore, and an internal quencher all contiguous with the primer.
  • the probe When not bound to the target, the probe remains in a stem - loop structure which keeps the quencher and fluorophore proximal and allows the quencher to absorb the fluorescence emitted from the fluorophore.
  • the primer will bind to the target and go through the first round of target synthesis.
  • the probe will be attached to the newly synthesized target region.
  • the spacer region prevents the DNA polymerase from copying the probe region and disrupting the stem structure.
  • next-generation sequencing offers high- throughput gene expression profiling, genome annotation or discovery of non-coding RNA. Sequence decoding is usually performed using dideoxy chain termination technology. With increasing importance of DNA sequencing in research and diagnostics, new methods were developed allowing a high- throughput sample treatment.
  • SBS sequencing-by-synthesis
  • pyrosequencing The important technological developments, summarized under the term next-generation sequencing, are based on the sequencing-by-synthesis (SBS) technology called pyrosequencing.
  • SBS sequencing-by-synthesis
  • pyrosequencing The transcriptomics variant of pyrosequencing technology is called short- read massively parallel sequencing or RNA-Seq [Stahl, 2013].
  • High-content screening also known as high-content analysis (HCA) or cellomics
  • HCS high-content analysis
  • HCA high-content analysis
  • cellomics is a method that is used in biological research and drug discovery to identify substances such as small molecules, peptides, or RNAi that alter the phenotype of a cell in a desired manner.
  • high content screening is a type of phenotypic screen conducted in cells. Phenotypic changes may include increases or decreases in the production of cellular products such as proteins and/or changes in the morphology (visual appearance) of the cell.
  • High content screening includes any method used to analyze whole cells or components of cells with simultaneous readout of several parameters.
  • cells are first incubated with the substance and after a period of time, structures and molecular components of the cells are analyzed.
  • the most common analysis involves labeling proteins with fluorescent tags, and finally changes in cell phenotype are measured using automated image analysis.
  • fluorescent tags with different absorption and emission maxima, it is possible to measure several different cell components in parallel.
  • the imaging is able to detect changes at a subcellular level (e.g., cytoplasm vs. nucleus vs. other organelles) [Alanine, 2008; Haskins, 2004].
  • the test compound is preferably a small molecule which binds to and occupies the active site of target polypeptide, thereby making the ligand binding site inaccessible to substrate such that normal biological activity is prevented.
  • small molecules include, but are not limited to, small peptides or peptide-like molecules.
  • Potential ligands which bind to a polypeptide or cell include, but are not limited to, the natural ligands of known target and analogues or derivatives thereof.
  • either the test compound can comprise a detectable label, such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase.
  • a detectable label such as a fluorescent, radioisotopic, chemiluminescent, or enzymatic label, such as horseradish peroxidase, alkaline phosphatase, or luciferase.
  • Detection of a test compound which is bound to the target polypeptide or cell can then be accomplished, for example, by direct counting of radioemmission, by scintillation counting, or by determining conversion of an appropriate substrate to a detectable product.
  • binding of a test compound to target polypeptide or cell can be determined without labeling either of the interactants.
  • BIA Bimolecular Interaction Analysis
  • SPR optical phenomenon surface plasmon resonance
  • Luciferases are commonly used as reporter genes in cell based assay formats for the characterization of second messenger and promotor activity modulators. These assays are used to test and characterize the activity of compounds or whole compound libraries. Often recombinant cell lines with luciferases under the control of second messenger responsive elements are used. Depending on the used luciferase the cell supernatant or cell lysate is used for activity testing. Usually the microtiter plate will be discarded after the measuring.
  • the cell lysate of the completed luminescence measurement could be used as a template lysate for a QPCR measurement without any further processing.
  • the lysate or an aliquot will be transferred to a QPCR useable microtiter plate. After addition of all reagent the QPCR could be performed.
  • Both readouts can be used to analyse the signaling cascade of a given target gene at different levels using the same sample, with one combinatorial assay set-up.
  • the modulation of the cAMP amount in a cell can be analysed with a reporter gene-based readout applying a cAMP responsive genetic element, whereas the activity of downstream regulated target genes may be detected by a subsequent QPCR assay within the same sample.
  • a cell based assay was performed as described in example 3.
  • the cells were incubated with increasing amounts of forskoline and incubated for the given time.
  • the cell lysate was used for the qualification of firefly luciferase mRNA.
  • Fig. 2 the relative light units for the different concentrations of forskoline are shown.
  • the luminescence was increased with increased concentrations of forskoline.
  • a part of the cell lysate was transferred to a QPCR microtiter plate.
  • the QPCR was performed as described in example 3.
  • the relative expression was calculated as described in example 2 and is shown in Fig. 1.
  • the relative expression of the firefly luciferase was increased with increasing concentrations of forskoline.
  • a cell based assay was performed as described in example 6. The cells were incubated with increasing amounts of JQl and incubated for the given time. After the luminescence measurement the cell lysate was used for the qualification of nanoluc luciferase mRNA. In Fig. 8 the relative light units for the different concentrations of JQl are shown. The luminescence was increased with increased concentrations of JQl .
  • RNA quantification or analysis of gene expression were combined with reporter gene based methods. Those methods are described, but not limited to, under “reporter genes", “expression analysis” and “multiplexing reporter gene assays”. The combination of methods is independent from the used microtiter plate format and could be used, but not limited to, 96, 384, 1536 and 6144 well formats.
  • QPCR is based on a sequence of biochemical based reactions, the efficiency and accuracy of which are greatly affected by the applied experimental conditions. All steps of the RNA quantification could be effected, for example (but not limited to): reverse transcription, DNA annealing, PCR and fluorescence detection.
  • Magnesium from the reporter gene assays has an influence on the transcriptional analysis assay (in particular QPCR).
  • Magnesium is a cofactor of firefly luciferase and necessary for a high sensitivity firefly luciferase based reporter gene assay [Zako, 2003].
  • the activity of the firefly luciferase directly depends on the Magnesium concentration in the reporter gene assay buffer (shown in Fig. 4 of [Zako, 2003]).
  • Magnesium is an important cofactor for PCR reactions which directly influences the accuracy with which the PCR primers hybridize with their template.
  • the concentration of Magnesium in PCR or QPCR reaction buffers therefore is a key parameter determining the results of the methods. Consequently, the optimization of PCR or QPCR processes mainly relates to the determination of the optimal amounts of Magnesium within the reaction solutions [Roux, 2009].
  • Luciferase is an intracellularly located enzyme. To measure the luminescence as a proportion of firefly luciferase activity it is therefore necessary to disrupt the cells in order to allow an interaction between the enzyme and its extracellularly located substrate. Cells are usually disrupted by the use of detergents. The concentration and type of detergent is cell and assay dependent [Brown, 2008; Schuck, 2003]. However, it is known in the art that the presence of detergents and the concentration of salts has a direct effect on QPCR efficacy [Shatzkes, 2014; Fig. 1].
  • Example 1 Design of primer probes for L32, Firefly luciferase, Nanoluc luciferase
  • cell lysates were transferred to 384-well or 1536-well QPCR microtiter plates. For 384-well 2 ⁇ L and for 1536-well 1 ⁇ cell lysate were transferred. The preparation of the cell lysates are described in examples 3-6.
  • the Custom qPCR kit from Eurogentec was used according to the manufacturer's specifications by using the following specifications.
  • the qPCR was performed in at total volume of 10 ⁇ per well with 2 ⁇ lysate, 1.5 ⁇ primer/probe mix (1.33 ⁇ each), 2.5 ⁇ master mix, 0.05 ⁇ enzyme mix and 1.45 ⁇ water
  • RNA Virus Master kit from Roche was used according to the manufacturer's specifications by using the following specifications.
  • the qPCR was performed in at total volume of 2 ⁇ per well with ⁇ ⁇ . lysate, 300 nL primer/probe mix (1.33 ⁇ each), 400 nL master mix, 40 nL enzyme mix and 260 nl water
  • CP value (as given from LC480 or LC1536 respectively) of Nanoluc luciferase: CP-Nano
  • CHO cells per well were seeded on 384-well microtiter plates in 50 ⁇ . complete growth medium. The cells are incubated for 24 hours under standard cell culture conditions (37 °C, 5% C02). After 24h the supernatant is removed and the compound is added Buffer X in the given final concentrations. The cell are incubated for 2 hours under standard conditions. The supernant is removed and ⁇ ⁇ buffer A (+ 10 U/well RNase Inhibitor) + RNase free water are added. The luminescence measuring is immediately started using a standard luminometer. The luminescence signal is measured for 60sec and integrated for 1 sec . The relative light units are shown in Fig. 2.
  • the cell lysate could directly be used for RNA or DNA quantification or analysis.
  • 2 ⁇ of the lysate is transferred to a 384well QPCR microtiter plate and the prepared Master Mix is added.
  • the cDNA synthesis is performed for 30 min at 48°C .
  • the QPCR is performed using a LC480 (Roche) with the following protocol: 10 min at 95°C, followed by 50 cycles of melting at 95°C for 15 sec and annealing/extending at 60°C for 1 min.
  • the relative expression is calculated as described under example 2.
  • the relative expression of the firefly luciferase is shown in Fig. 1.
  • Buffer A 50mM Tris(hydroxymethyl)-aminometha (pH 8), 40mM Natrium chloride, 1.5 mM Magnesium chloride, 0.5% Octylphenoxy poly(ethyleneoxy)ethanol (IGEPAL® CA-630), 50 mM Guanidiniumthiocyanat, 23.85 mM Adenosintriphosphat, 1.215 mM Acetyl-CoA, 2.115 mM D- Luciferin
  • Buffer X 2mM Calcium chloride, 20mM 2-[4-(2-hydroxyethyl)piperazin-l -yl]ethanesulfonic acid, 130mM Natrium chloride, 5mM Kalium chloride, 5mM Sodium hydrogen carbonate, 2mM Magnesium chloride hexahydrate
  • Example 4 Combination of firefly luciferase with QPCR - protocol 2 in 384well format
  • CHO cells per well were seeded on 384well microtiter plates in 50 ⁇ . complete growth medium .
  • the cells are incubated for 24 hours under standard cell culture conditions (37 °C, 5% C02). After 24h the supernatant is removed and the compound is added Buffer X in the given final concentrations.
  • the cell are incubated for 2 hours under standard conditions.
  • the supernant is removed and ⁇ ⁇ buffer B (+ 10 U/well RNase Inhibitor) + RNase free water are added.
  • the luminescence measuring is immediately started using a standard luminometer.
  • the luminescence signal is measured for 60sec and integrated for 1 sec .
  • the relative light units are shown in Fig. 2.
  • the cell lysate could directly be used for RNA or DNA quantification or analysis.
  • 2 ⁇ of the lysate is transferred to a 384well QPCR microtiter plate and the prepared Master Mix is added.
  • the cDNA synthesis is performed for 30 min at 48°C .
  • the QPCR is performed using a LC480 (Roche) with the following protocol: 10 min at 95°C, followed by 50 cycles of melting at 95°C for 15 sec and annealing/extending at 60°C for 1 min. .
  • the relative expression is calculated as described under example 2.
  • the relative expression of the firefly lucif erase is shown in Fig. 3. Used buffers:
  • Buffer B 120mM N-(Tri(hydroxymethyl)methyl)glycin, 15.6 mM Magnesium chloride, 1.56 mM Ethylendiamintetraacetat, 198 mM Dithiothreitol, 31.8 mM Adenosintriphosphat, 1.62 mM Acetyl- CoA, 2.82 mM Luciferin
  • CHO cells per well were seeded on 384well microtiter plates in 50 ⁇ . complete growth medium. The cells are incubated for 24 hours under standard cell culture conditions (37 °C, 5% C02). After 24h the supernatant is removed and the compound is added Buffer X in the given final concentrations. The cell are incubated for 2 hours under standard conditions. The supernant is removed and ⁇ ⁇ buffer C (+ 10 U/well RNase Inhibitor) + RNase free water are added. The luminescence measuring is immediately started using a standard luminometer. The luminescence signal is measured for 60sec and integrated for 1 sec . The relative light units are shown in Fig. 2.
  • the cell lysate could directly be used for RNA or DNA quantification or analysis.
  • 2 ⁇ of the lysate is transferred to a 384well QPCR microtiter plate and the prepared Master Mix is added.
  • the cDNA synthesis is performed for 30 min at 48°C .
  • the QPCR is performed using a LC480 (Roche) with the following protocol: 10 min at 95°C, followed by 50 cycles of melting at 95°C for 15 sec and annealing/extending at 60°C for 1 min. .
  • the relative expression is calculated as described under example 2.
  • the relative expression of the firefly luciferase is shown in Fig. 5. Used buffers:
  • Buffer C Luciferase Assay System (El 500, Promega) Assay protocol:
  • CHO cells per well were seeded on 1536-well microtiter plates in 1 L complete growth medium .
  • the cells are incubated for 24 hours under standard cell culture conditions (37 °C, 5% C02). After 24 h Buffer X is added with compounds in the given concentrations.
  • the cell are incubated for 6 hours under standard conditions.
  • the supernant is removed and 1 ⁇ ⁇ buffer D is added.
  • the luminescence measuring is immediately started using a standard luminometer.
  • the luminescence signal is measured for 60 sec and integrated for 1 sec .
  • the relative light units are shown in Fig. 2.
  • buffer E (containing 1 U/well RNase Inhibitor) is added.
  • the cell lysate could directly be used for RNA or DNA quantification or analysis.
  • 1 ⁇ of the lysate is transferred to a 1536-well QPCR microtiter plate and the prepared Master Mix is added.
  • the cDNA synthesis is performed for 30 min at 48°C .
  • the QPCR is performed using a LC1536 (Roche) with the following protocol: 10 min at 95°C, followed by 50 cycles of melting at 95°C for 15 sec and annealing/extending at 60°C for 1 min. .
  • the relative expression is calculated as described under example 2.
  • the relative expression of the nanoluc luciferase is shown in Fig. 7. Used Buffers:
  • Buffer D Nano-Glo® Luciferase Assay (Nl 130, Promega)
  • Buffer E 1 ⁇ Triton Buffer (PAA, T21-160) + 5 ⁇ RNase free water
  • Fig. 1 combination of firefly luciferase with QPCR - protocol 1 (expression)
  • Fig. 2 combination of firefly luciferase with QPCR - protocol 1 (luminescence)
  • Fig. 3 combination of firefly luciferase with QPCR - protocol 2 (expression)
  • Fig. 4 combination of firefly luciferase with QPCR - protocol 2 (luminescence)
  • Fig. 5 combination of firefly luciferase with QPCR - protocol 3 (expression)
  • Fig. 6 combination of firefly luciferase with QPCR - protocol 3 (luminescence)
  • Fig. 7 combination of nanoluc luciferase with QPCR - protocol 4 (expression)
  • Fig. 8 combination of nanoluc luciferase with QPCR - protocol 4 (luminescence)
  • Fig. 9 spectra of selected fluorescent labels
  • Fig. 10 absorption and fluorescnce spectrum of firefly luciferase substrate
  • Fig. 1 shows the relative expression of firefly luciferase using protocol 1 as described under example 3.
  • ⁇ relative expression
  • Fig. 2 shows the relative light units (RLU) of firefly luciferase using protocol 1 as described under example 3.
  • ⁇ Total Light emitted by the luciferase-catalyzed chemiluminescent reaction, in relative light units (RLU), measured 60 seconds with integration period of 1 second
  • Fig. 3 shows the relative expression of firefly luciferase using protocol 2 as described under example 4.
  • Fig. 4 shows the relative light units (RLU) of firefly luciferase using protocol 1 as described under example 4.
  • ⁇ Total Light emitted by the luciferase-catalyzed chemiluminescent reaction, in relative light units (RLU), measured 60 seconds with integration period of 1 second
  • Fig. 5 shows the relative expression of firefly luciferase using protocol 1 as described under example 5.
  • Fig. 6 shows the relative light units (RLU) of firefly luciferase using protocol 1 as described under example 5.
  • B Total Light emitted by the luciferase-catalyzed chemiluminescent reaction, in relative light units (RLU), measured 60 seconds with integration period of 1 second Fig.
  • Fig. 8 shows the relative light units (RLU) of nanoluc luciferase using protocol 4 as described under example 6.
  • ⁇ Total Light emitted by the luciferase-catalyzed chemiluminescent reaction, in relative light units (RLU), measured 60 seconds with integration period of 1 second
  • Fig. 9 shows the fluorescence spectra of selected fluophores which could be used for probe labeling in QPCR. (from Fig. 1 [Van Poucke, 2012]).
  • Fig. 10 shows the absorption and fluorescnce spectrum of firefly luciferase substrate (from Fig. 1 [Hiyama, 2012]) Listing of Sequences
  • SEQ ID NO:4 forward primer firefly luciferase
  • SEQ ID NO: 6 probe firefly luciferase
  • SEQ ID NO: 7 forward primer nanoluc luciferase
  • SEQ ID NO: 8 reverse primer nanoluc luciferase
  • SEQ ID NO: 9 probe nanoluc luciferase
  • SEQ ID NO: l 1 nucleotide sequence of firefly luciferase
  • SEQ ID NO: 12 nucleotide sequence of nanoluc luciferase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé d'analyse des effets d'un ou de plusieurs composés d'essai sur des cellules ou des tissus, qui comprend au moins une étape comprenant un dosage cellulaire, et une étape comprenant une analyse d'expression associée auxdites cellules ou tissus.
PCT/EP2018/053810 2017-02-16 2018-02-15 Dosages de gènes rapporteurs et analyse transcriptionnelle combinés WO2018149929A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17156484.2 2017-02-16
EP17156484 2017-02-16

Publications (1)

Publication Number Publication Date
WO2018149929A1 true WO2018149929A1 (fr) 2018-08-23

Family

ID=58094231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/053810 WO2018149929A1 (fr) 2017-02-16 2018-02-15 Dosages de gènes rapporteurs et analyse transcriptionnelle combinés

Country Status (1)

Country Link
WO (1) WO2018149929A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046517A1 (fr) * 2006-10-16 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Ctgf utilisé comme biomarqueur, cible thérapeutique et diagnostique
US20120129857A1 (en) * 2010-11-18 2012-05-24 Bayer Pharma Aktiengesellschaft Substituted sodium 1H-pyrazol-5-olate
US20160122325A1 (en) * 2014-11-03 2016-05-05 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
WO2016131808A1 (fr) * 2015-02-20 2016-08-25 Bayer Pharma Aktiengesellschaft Dérivés de 1,3,4-thiadiazol-2-yl-benzamide utilisés en tant qu'inhibiteurs de la voie de signalisation wnt
WO2016177658A1 (fr) * 2015-05-05 2016-11-10 Bayer Pharma Aktiengesellschaft Dérivés de cyclohexane à substitution amido

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046517A1 (fr) * 2006-10-16 2008-04-24 Bayer Schering Pharma Aktiengesellschaft Ctgf utilisé comme biomarqueur, cible thérapeutique et diagnostique
US20120129857A1 (en) * 2010-11-18 2012-05-24 Bayer Pharma Aktiengesellschaft Substituted sodium 1H-pyrazol-5-olate
US20160122325A1 (en) * 2014-11-03 2016-05-05 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
WO2016131808A1 (fr) * 2015-02-20 2016-08-25 Bayer Pharma Aktiengesellschaft Dérivés de 1,3,4-thiadiazol-2-yl-benzamide utilisés en tant qu'inhibiteurs de la voie de signalisation wnt
WO2016177658A1 (fr) * 2015-05-05 2016-11-10 Bayer Pharma Aktiengesellschaft Dérivés de cyclohexane à substitution amido

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
"The American Heritage Dictionary of the English Language, 4th ed.", 2000, HOUGHTON MIFFLIN COMPANY
ALANINE, NAT REV DRUG DISCOV, vol. 2, no. 5, May 2003 (2003-05-01), pages 369 - 78
ARTMANN: "Bioengineering in Cell and Tissue Research", 2008, SPRINGER, ISBN: 3540754083, article "chapter "Reporter genes in cell based ultra High Throughput Screening""
BROWN, J. R. SOC. INTERFACE, vol. 5, 2008, pages S131 - S138
BROWN, NUCLEIC ACIDS RES., vol. 28, no. 19, 1 October 2000 (2000-10-01), pages 3752 - 61
BUSTIN, J BIOMOL TECH., vol. 15, no. 3, September 2004 (2004-09-01), pages 155 - 66
ECKHARD, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 271, 2000, pages 726 - 730
GROOM, NAT REV DRUG DISCOV, vol. l, no. 9, September 2002 (2002-09-01), pages 727 - 30
HASKINS, TRENDS BIOTECHNOL, vol. 22, no. 1, January 2004 (2004-01-01), pages 15 - 22
HASTINGS, J CELL PHYSIOL., vol. 77, no. 3, June 1971 (1971-06-01), pages 305 - 12
HIISER, CLIN LAB., vol. 53, no. 1-2, 2007, pages 77 - 9
HIYAMA, PHOTOCHEMISTRY AND PHOTOBIOLOGY, vol. 88, 2012, pages 889 - 898
KRAMER, NAT BIOTECHNOL., vol. 14, no. 3, March 1996 (1996-03-01), pages 303 - 8
LI, EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 24, no. 11, 2014, pages 1199 - 1227
LINKE, METHODS ENZYMOL., vol. 463, 2009, pages 603 - 17
LITTLE, NAT BIOTECHNOL., vol. 17, no. 8, August 1999 (1999-08-01), pages 804 - 7
MOREIRA, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 327, 2005, pages 473 - 484
PFLEGER, BR J PHARMACOL, 28 August 2015 (2015-08-28)
RAUX, COLD SPRING HARB PROTOC, vol. 4, April 2009 (2009-04-01)
RHOADS, NUCLEIC ACIDS RES., vol. 18, no. 21, 11 November 1990 (1990-11-11), pages 6409 - 12
RODA, ANAL BIOANAL CHEM, vol. 398, 2010, pages 227 - 238
SCHUCK, PNAS, vol. 100, 2003, pages 5795 - 5800
SHATZKES, SCIENTIFIC REPORTS, vol. 4, 2014
SKOBLOV, METHODS MOL BIOL, vol. 784, 2011, pages 1 - 13
STAHL, CURR OPIN BIOTECHNOL, vol. 24, no. 1, February 2013 (2013-02-01), pages 22 - 30
TOLLIDAY, METHODS MOL BIOL, vol. 486, 2009, pages 1 - 12
TSIEN, CURR BIOL., vol. 6, no. 2, 1 February 1996 (1996-02-01), pages 178 - 82
TURCATTI, BIOCHEMISTRY, vol. 34, no. 12, 28 March 1995 (1995-03-28), pages 3972 - 80
VAN POUCKE, BIOTECHNIQUES, vol. 52, no. 2, 2012, pages 81 - 6
WILLIAMS, GENOME RES, vol. 6, no. 10, October 1996 (1996-10-01), pages 995 - 1001
YOUVAN, BIOTECHNOLOGY (N Y)., vol. 13, no. 2, February 1995 (1995-02-01), pages 151 - 4
YOUVAN, GENE, vol. 173, no. 1, 1996, pages 13 - 7
ZAKO, BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1649, 2003, pages 183 - 189

Similar Documents

Publication Publication Date Title
Singh et al. Quantitative real-time PCR: recent advances
CA2556418C (fr) Methodes et matieres utilisant des sondes de signalisation
EP3303613B1 (fr) Procédé pour détecter l'activité d'une polymérase
Guo et al. Hybridization chain reactions on silica coated Qbeads for the colorimetric detection of multiplex microRNAs
CN102071251B (zh) 一种pcr检测核酸的方法
JP2012235778A (ja) アセトアルデヒド脱水素酵素２及びアルコール脱水素酵素２の遺伝子変異を同時に検出する方法
JP2017136086A (ja) 標的核酸の検出方法及びキット
Mashimo et al. Detection of small RNA molecules by a combination of branched rolling circle amplification and bioluminescent pyrophosphate assay
US20050186624A1 (en) Method of detection in vitro of a target substance in a sample comprising the labelling of said substance with a reporter gene and with the sequences necessary for the expression of said reporter gene in vitro
WO2018149929A1 (fr) Dosages de gènes rapporteurs et analyse transcriptionnelle combinés
EP2971131A1 (fr) Procédés et matériels utilisant des sondes de signalisation
US20090191562A1 (en) METHOD FOR ASSAYING REG IV mRNA
US11130988B2 (en) Method for detecting a plurality of short-chain nucleic acid in sample, combinatorial analysis kit, analysis kit supply management method
JP5481841B2 (ja) サイトケラチン１９ｍＲＮＡの測定方法
US20170081713A1 (en) Multivalent probes having single nucleotide resolution
KR100872001B1 (ko) 이종 핵 리보뉴클레오티드 단백질 Ｂ１(ｈｎＲＮＰ Ｂ１)ｍＲＮＡ의 측정 방법
US7393641B2 (en) Method of detecting micrometastasis
Huang et al. Selective labeling and detection of specific RNAs in an RNA mixture
JP5782704B2 (ja) ＧＡＰＤＨｍＲＮＡの測定方法
KR100825154B1 (ko) 모세관 전기영동-단일쇄 형태변환 다형성을 이용한 세포내ｍＲＮＡ 정량 방법
JP2008113619A (ja) 発光持続性の高いルシフェラーゼを用いた破壊系細胞アッセイ法
IL143637A (en) Method for detecting in vitro a target substance in a sample comprising the labelling of said substance with a reporter gene and the sequences required for expressing said reporter gene in vitro
US20070082348A1 (en) Discrimination method of target base in DNA, and allele specific primer used in the method of the same
WO2007020708A1 (fr) Méthode pour déterminer une base cible incluse dans de l’adn et amorce allèle-spécifique à utiliser dans la méthode

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18710766

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18710766

Country of ref document: EP

Kind code of ref document: A1